Better Health for All

180 Life Sciences is developing treatments for conditions like Dupuytren's contracture and inflammatory diseases, which aligns with the 'Better Health for All' value. Phase 2b trial results for adalimumab showed a reduction in nodule hardness and size in Dupuytren's disease patients

, , , . The treatment is likely cost-effective compared to current NHS practices, costing £14,593 per QALY gained versus the NHS threshold of £20,000 , , , . The company is also developing synthetic cannabinoid analogs (SCAs) for various conditions, including arthritis and pain , , . A clinical trial with 12 volunteers showed that solid formulations of CBD were well-tolerated , . The company is seeking regulatory approval in the UK and US for its Dupuytren's disease treatment . The company's focus on developing treatments and the cost-effectiveness of adalimumab support a positive score. However, the early stage of development and lack of information on accessibility limit a higher score.

Fair Money & Economic Opportunity

180 Life Sciences Corp. is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, with a recent strategic entry into the online gaming industry.

The company's business model does not involve offering lending, deposit, or other financial services to consumers. Therefore, all KPIs related to financial products, services, or customer financial outcomes are not applicable to its operations.

Fair Trade & Ethical Sourcing

No specific, concrete data points related to fair trade and ethical sourcing, such as fair-trade certification share, audit frequency, forced/child labor incidents, traceability coverage, remediation speed, ethical clause coverage, materials risk index, or supplier diversity spend, were found in the provided articles.

The articles either resulted in 404 errors or explicitly stated that no relevant data for these metrics was available.

Honest & Fair Business

No specific, quantitative evidence was found in the provided articles for any of the KPIs related to Honest & Fair Business. While articles mention the company regaining compliance with Nasdaq rules regarding its audit committee composition, this does not provide the percentage of the entire board free from conflicts of interest.

Similarly, the existence of a 'Code of Ethics' is noted, but there is no detail on the presence or strength of a formal whistle-blower protection policy or an anti-corruption policy. No data is available for regulatory fines, transparency index scores, financial restatements, audit coverage percentage, ESG controversy scores, complaint resolution times, or third-party verification of ethical claims.

Kind to Animals

180 Life Sciences Corp. engages in animal testing.

However, no specific quantitative data or details are available regarding the volume of animals used, the extent of non-animal testing methods employed, the company's animal testing policy, or any investments in animal-free alternatives. There is also no information on cruelty-free certifications, humane certifications for operations, wildlife conservation impact, ethical input substitution, supplier audits for welfare compliance, or sourcing practices for animal products.

No War, No Weapons

180 Life Sciences Corp. is a clinical-stage biotechnology company that is pivoting to the iGaming sector.

Multiple articles explicitly state that the company has no revenue from arms or defense contracts, is not involved in dual-use technology, and has no sales to embargoed or sanctioned regimes. The company's patents relate to medical applications, such as preventing post-operative cognitive decline and treating fibrotic disorders. There is no mention of any defense-related business activities, exports, lobbying, humanitarian procurement, human rights due diligence in conflict areas, Arms Trade Treaty compliance, AI systems for military use, UN Guiding Principles alignment, surveillance contracts, ethical red lines, controversial weapons, war-related supply chain audits, conflict-related partner reviews, defense divestment, conflict minerals, peace technology investment, or procurement from conflict-affected areas. Therefore, all KPIs are scored as 'N/A' due to the absence of any defense or arms-related activities in the company's core business or operations.

Planet-Friendly Business

No specific, concrete data points related to Planet-Friendly Business KPIs, such as greenhouse gas emissions, renewable energy use, water consumption, waste diversion, or environmental certifications, were found in the provided articles.

The articles either explicitly state that sustainability data is unavailable for ATNF.US or provide a general 'SDG Transparency Score' which does not map to any specific environmental performance or management KPI in the rubric.